https://www.gosh.nhs.uk/our-research/our-research-infrastructure/nihr-great-ormond-street-hospital-brc/brc-news/funding-provided-develop-new-therapy-acute-liver-failure/
Funding provided to develop new therapy for acute liver failure
9 Sep 2015, 4:50 p.m.

BRC-supported researcher Dr Kevin Mills has been awarded funding from the NIHR to investigate the regenerative ability of the liver following acute liver failure (ALF). If successful, the team hope that their research will lead to a novel therapy that could buy patients enough time to allow their livers to regenerate naturally, avoiding the need for liver transplantsThis research will be led by Professor Anil Dhawan at Kings College London in collaboration with Dr Mills at UCL Institute of Child Health. Specifically, the team aim to develop a novel technique where human liver cells grown in the lab are encapsulated in a material called alginate and delivered to a patient to help their ailing liver regenerate. Encasing the liver cells in alginate is particularly important as it reduces the need for immunosuppression.
Studies in the lab will focus on the feasibility of this novel therapy under lab conditions.

Teenager off to university after life-changing gene therapy
A teenager with a rare, life-limiting genetic condition is off to university after receiving a gene therapy that changed his life.

Stem cell treatment can improve rare skin condition in children
Children with a rare skin condition have found their symptoms have improved through taking part in the largest clinical trial of its kind, led by clinicians at Great Ormond Street Hospital for Children (GOSH).

Young people donate tissue samples to unlock mysteries of arthritis
A new groundbreaking study led by researchers at the University of Birmingham, Great Ormond Street Hospital, University College London and Birmingham Children’s Hospital has revealed important clues into what is driving arthritis in children.

Toddler doing well after receiving newest gene therapy available on NHS
A toddler with a life-limiting and life-threatening rare disease is the youngest to be treated with the newest gene therapy available on the NHS at GOSH.